cialis au meilleur prix compro viagra online comprare cialis online consigli
levitra 20 mg preisvergleich kamagra apotek cialis a vendre montreal
  • acquisto viagra via internet billiger viagra viagra se vende en farmacias
  • generic viagra sydney viagra patent australia expiry much does viagra cost australia
    cvs pharmacy valtrex price crisplus orlistat 120 mg efectos antibiotic sulfameth trimethoprim
    cheap adobe acrobat 9 download fireworks for mac windows 7 ultimate 64 bit oem
  • after effects cs6 buying office 2007 enterprise cheap adobe dreamweaver cs5
  • windows 7 home premium price best buy best price project 2013 professional microsoft word 2007 buy

    GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy

    Sat, Oct 15, 2011

    Oral Cancer News

    Author: Chien-Yu Lin et al.

    Oral cavity cancers (ORC) are the most common cancers, and standard treatment is radical surgery with postoperative radiotherapy. However, locoregional failure remains a major problem, indicating radioresistance an important issue.
    Our previous work has shown that GP96 contributed to radioresistance in nasopharyngeal and oral cancer cell lines. In this study, we determined clinical significance of GP96 in ORC by evaluation of GP96 expression and its association with disease prognosis in patients receiving radiotherapy

    Total of 79 ORC patients (77 males, median age: 48 years old) receiving radical surgery and postoperative radiotherapy between Oct 1999 and Dec 2004 were enrolled.

    Patients in pathological stages II, III and IV were 16.5%, 16.5% and 67%, respectively. For each patient, a pair of carcinoma tissue and grossly adjacent normal mucosa was obtained.

    GP96-expression was examined by western blot analysis, and the association with clinicopathological status was determined.

    Three-year locoregional control (LRC), distant metastasis-free survival (DMFS), disease-specific survival (DSS) and overall survival (OS) rates were 69%, 79%, 63% and 57%, respectively. We found that 55 patients (70%) displayed GP96-overexpression in the tumor tissue, which correlated with a higher pN stage (p=0.020) and tumor depth (>10 mm) (p=0.045).

    Nodal extracapsular spreading (ECS) and GP96-overexpression predicted adverse LRC (p=0.049 and p=0.008). When stratified by nodal ECS, the adverse impact of GP96 remained significant in three-year LRC (p=0.004).

    In multivariate analysis, GP96-overexpression was also an independent predictor of LRC, DSS and OS (p=0.018, p=0.011 and p=0.012).

    GP96 may play roles in radioresistance which attributes to tumor invasiveness in oral cancer patients receiving radiotherapy. GP96 may serve as a novel prognostic marker of radiotherapy.

    However, further independent studies are required to validate our findings in a larger series.

    Authors: Chien-Yu Lin, Ting-Yang Lin, Hung-Ming Wang, Shiang-Fu Huang, Kang-Hsing Fan, Chun-Ta Liao, I-How Chen, Li-Yu Lee, Yan-Liang Li, Yin-Ju Chen, Ann-Joy Cheng, Joseph Chang

    Source: Radiation Oncology 2011, 6:136

    Print Friendly
    Be Sociable, Share!
    , , , , ,

    Leave a Reply

    You must be logged in to post a comment.